Helius Medical Technologies Appoints Jeffrey S. Mathiesen to its Board of Directors
April 22 2020 - 7:05AM
Helius Medical Technologies, Inc. (NASDAQ: HSDT) (TSX: HSM)
(“Helius” or the “Company”), a neurotech company focused on
neurological wellness, today announced the appointment of Jeffrey
S. Mathiesen, CPA, to its Board of Directors, effective as of June
9, 2020. Upon his appointment, Mr. Mathiesen will serve as Chair of
the Company’s Audit Committee.
“Jeff joins our Board of Directors with more
than 25 years of experience as Chief Financial Officer of numerous
growth-oriented, technology-based companies, including significant
experience in the healthcare sector,” said Philippe Deschamps,
Chief Executive Officer of Helius Medical Technologies and Chairman
of the Board of Directors. “I am very honored to welcome such an
accomplished financial expert to our Board and look forward to
leveraging his expertise as Chair of our Audit Committee.”
Mr. Mathiesen’s career experience includes
executive and financial management positions with both public and
private companies. He most recently worked for Teewinot Life
Sciences Corporation, a privately held global leader in the
biosynthetic development and production of cannabinoids and their
derivatives for consumer and pharmaceutical products, from March
2019 to December 2019, where he served as Chief Financial Officer
and later Advisor to the CEO. Mr. Mathiesen previously served as
Chief Financial Officer of Gemphire Therapeutics Inc., a publicly
traded, clinical-stage biopharmaceutical company, from 2015 to
2018. Prior to joining Gemphire Therapeutics, Mr. Mathiesen served
as Chief Financial Officer of Sunshine Heart, Inc., a publicly
traded medical technology company, from 2011 to 2015. Mr. Mathiesen
began his career at Deloitte & Touche LLP in 1983. He received
a B.S. in Accounting from the University of South Dakota and is
also a Certified Public Accountant (CPA).
Mr. Mathiesen has served as Director and Audit
Committee Chair of Sun BioPharma, Inc., a publicly-traded
biopharmaceutical company developing therapies for pancreatic
diseases, since 2015, NeuroOne Medical Technologies Corporation, a
publicly-traded medical technology company providing
neuromodulation continuous EEG monitoring and treatment solutions
for patients suffering from epilepsy and other nerve related
disorders, since 2017, and eNeura, Inc., a privately-held medical
technology company providing therapy for both acute treatment and
prevention of migraine, from 2018 to 2020.
About Helius Medical Technologies,
Inc.Helius Medical Technologies is a neurotech company
focused on neurological wellness. The Company’s purpose is to
develop, license and acquire unique and non-invasive platform
technologies that amplify the brain’s ability to heal itself. The
Company’s first product in development is the Portable
Neuromodulation Stimulator (PoNSTM). For more information, visit
www.heliusmedical.com.
About the PoNS Device and PoNS
TreatmentThe Portable Neuromodulation Stimulator (PoNS) is
an authorized class II, non-implantable medical device authorized
for sale in Canada. PoNS is intended as a short term treatment (14
weeks) of chronic balance deficit due to mild-to-moderate traumatic
brain injury and is to be used in conjunction with physical therapy
and indicated as a short term treatment (14 weeks) of gait deficit
due to mild and moderate symptoms from MS and is to be used in
conjunction with physical therapy. The PoNS is an investigational
medical device in the United States, the European Union, and
Australia, and is currently under review for clearance by the AUS
Therapeutic Goods Administration. PoNS Treatment is currently not
commercially available in the United States, the European Union or
Australia.
Cautionary Disclaimer Statement:
Certain statements in this news release are not
based on historical facts and constitute forward-looking statements
or forward-looking information within the meaning of the U.S.
Private Securities Litigation Reform Act of 1995 and Canadian
securities laws. All statements other than statements of historical
fact included in this news release are forward-looking statements
that involve risks and uncertainties. Forward-looking statements
are often identified by terms such as “believe,” “continue,” “look
forward,” “will” and similar expressions. Such forward-looking
statements include, among others, statements regarding the
Company’s future clinical and regulatory development plans for the
PoNS, the success of the Company’s planned study, business and
commercialization initiatives and objectives, the potential receipt
of regulatory clearance of the PoNS device in the United States,
the European Union and Australia and the Company’s revenue
guidance.
There can be no assurance that such statements
will prove to be accurate and actual results and future events
could differ materially from those expressed or implied by such
statements. Important factors that could cause actual results to
differ materially from the Company’s expectations include the
uncertainties associated with clinical trial enrollments and the
results of clinical trials, uncertainties associated with the
clinical development process and FDA regulatory submission and
approval process, including the Company’s capital requirements to
achieve its business objectives and other risks detailed from time
to time in the filings made by the Company with securities
regulators, and including the risks and uncertainties about the
Company’s business described in the “Risk Factors” sections of the
Company’s Annual Report on Form 10-K for the year ended December
31, 2019, and its other filings with the United States Securities
and Exchange Commission and the Canadian securities regulators,
which can be obtained from either at www.sec.gov or
www.sedar.com.
The reader is cautioned not to place undue
reliance on any forward-looking statement. The forward-looking
statements contained in this news release are made as of the date
of this news release and the Company assumes no obligation to
update any forward-looking statement or to update the reasons why
actual results could differ from such statements except to the
extent required by law.
The Toronto Stock Exchange has not reviewed and
does not accept responsibility for the adequacy or accuracy of the
content of this news release. Investor Relations
Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.Mike Piccinino,
CFA443-213-0500investorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Sep 2023 to Sep 2024